u/tomonota

Institutions and Hedge funds own = 26.79% of shares- they are playing for our side from the Big Boys' team. Note our 50 day moving average was $1.03 as of yesterday. Evidently rising as shares have traded ~$1.15 plus or minus this week.

The attempt to push inovio below $1 failed and the team of shorts are looking at huge losses on the 16 million short shares they borrowed and have to return. Inovio will never be delisted from the Nasdaq stock exchange. The squeeze will continue through next week for the monthly stock expiration date will require shorts to cover or else continue to pay for their underwater positions. Profitez mes amis, the money will flow in through Friday close of the market. Note we’re on the verge of the issue price of the company’s $18 million share sale at $1.10, which is not yet available for sale yet, but check the date shares become available for your own information. This may present a temporary ceiling price for shares; but the $18 million dollars will extend the company runway for launching Ino-3107, following the 10/30/26 expected PDUFA date- after which will bring product sales revenues. Btw consider the influence that ApolloBio sales of 3100 will have on the share price- 11% is inovio’s % of the profit and analysts value the company around $4. Don’t tell the short schmucks about that, please- we need them to keep selling us cheap shares (!)

Grok finds 3 forecasts for Inovio price in 2027 from $2.50-$4 and is my first time using Grok.

From (revised previous) post about the value of the Ino-Apollobio 3100 profitsharing agreement with ApolloBio from Stocktwits.com:

"...If I recall, the profit sharing % is in the low teens, probably a sliding rate based on volume, between 11%-14%; I believe ApolloBio is aiming for a worldwide license; so the market per WHO estimate is 167 million cases...will take time to deliver all that product but a long term agreement worth, assume $900 per treatment, 50% profit per shot, $450 *165 million treatments= $75 million; as to which (?) 11% is =$8.2 million cumulatively, per the agreement. In effect a deferred revenue source of $8.2MM per share. Wall Street values the shares at 8.76 times Book Value, hence $72 MM in future Sales assumed, $72MM cash revenue less expenses $24 MM/yr. = net earnings $48 MM so Book Value $48MM; X 8.76,= $420MM div. by 100# MM shares= $4.20 a share.

All for under a buck a better deal than a pack of beer nuts.

Vaccine assault led by HHS Seceratry

The related dilution is likely to create many times more sales from the pipeline cancer and infectious disease treatments awaiting approval with self funded regulatory approvals.

INO has greater potential to work with non-US BP manufacturers or is it my imagination?? ApolloBio and AZN being 2 examples.

FYI, INO-4201 IS A IMMUNE BOOSTER VACCINE FOR THE PREVENTION OF EBOLA AND IS PROPOSED FOR USE WITH ERVEBO.

REMDEIVIR IS AN ANTIVIRAL WHICH IS BEING TRIALED vs. A NEW mAB (ANTIVIRAL) TREATMENT, MBP-134, IN THE D.R.C. There are about 1,800 demonstrated cases of Ebola with about 34% of those fatalities IN THE CONGO. Reports indicate that aid workers are having work stoppages to protest the lack of salaries since the epidemic began.

The list price of Hympavzi without insurance and before discounts is $795,000/year. The high cost of treatment for rare diseases is an apparent burden for patients and families. Fortunately there may soon be alternative(s) available for some patients, viz a viz Inovio and other researchers.

Hemophilia can cause bleeding from a cut, or even just a severe impact, especially in the brain, thorax or abdomen. Current treatments include Clotting Factor blood based products; Emicizumab, Hemlibra (Roche); and Gene Therapy Valoctocogene, Roctovian, (approved June 2023).

(Note the durability of dMABs refreshing of a Covid 19 vaccine from Astrazeneca was shown to have persistence in the immune system for up to 72 weeks, approx. 500 days or ~17 months.)

So I am grateful to heaven that I don't have hemophilia Type A but also I thank god for Inovio for the greatest success in improving the lives of these hemophilia-afflicted patients. If this disease can be eliminated, or remediated, then my shares will have done more than return my investment or deliver a profit to me: they will have remediated a dangerous, difficult lifelong condition.

Which may be the first of many life-threatening conditions which could halt or deter the risk of death from GBM (brain) and Throat cancers; cervical and anal HSIL dysplasia tumor, and RRP, a severe growth of papillomas in the throat and lungs. That would be a bigger win than any stock investment could have made. Don't let the Short army attacks deter you from doing a good and just act: Inovio is too important a technology and too well-known to die out: we will endure and we will win over the Haters. Time is on our side. Our research is 40 years in the making. Let it see the light of day.

Hemophilia can cause bleeding from a cut, or even just a severe impact, especially in the brain, thorax or abdomen. Current treatments include Clotting Factor blood based products; Emicizumab, Hemlibra (Roche); and Gene Therapy Valoctocogene, Roctovian, (approved June 2023).

(Note the durability of dMABs refreshing of a Covid 19 vaccine from Astrazeneca was shown to have persistence in the immune system for up to 72 weeks, approx. 500 days or ~17 months.)

So I am grateful to heaven that I don't have hemophilia Type A but also I thank god for Inovio for the greatest success in improving the lives of these hemophilia-afflicted patients. If this disease can be eliminated, or remediated, then my shares will have done more than return my investment or deliver a profit to me: they will have remediated a dangerous, difficult lifelong condition.

Which may be the first of many life-threatening conditions which could halt or deter the risk of death from GBM (brain) and Throat cancers; cervical and anal HSIL dysplasia tumor, and RRP, a severe growth of papillomas in the throat and lungs. That would be a bigger win than any stock investment could have made. Don't let the Short army attacks deter you from doing a good and just act: Inovio is too important a technology and too well-known to die out: we will endure and we will win over the Haters. Time is on our side. Our research is 40 years in the making. Let it see the light of day.